Topics: Pharmacogenomics, Pharmacoepidemiology, DRUG SPECIFICITY, receptor classification, drug concentration, drug effect, spare receptors, COMPETITIVE ANTAGONISM, Irreversible Competitive Antagonism, Partial Agonists, Constitutive Receptor Activation, Inverse Agonists, two-state receptor model, Biased Agonism, Allosteric Modulation, Chemical Antagonism, Pharmacokinetic Antagonism, Receptor–Response Linkage, Physiological Antagonism, Desensitisation, Tolerance, Altered Drug Metabolism, Binding Reaction, Drug–Receptor Interactions, Receptor mechanisms, Ion Channels, Enzymes, Receptor Proteins, Receptor Heterogeneity, Ligand-Gated Ion Channels, Gating Mechanism, G Protein–Coupled Receptors, Proteinase-Activated Receptors, G proteins, phospholipase C, inositol phosphate system, Inositol phosphates, intracellular calcium, Diacylglycerol, protein kinase, MAP kinase system, GPCR desensitisation, Biopharmaceuticals, Chemical Mediators, Presynaptic Modulation, Postsynaptic Modulation, Cholinergic transmission, Nicotinic Receptors, Acetylcholine, Muscarinic Agonists, Muscarinic Antagonists, Ganglion Stimulants, Ganglion-Blocking Drugs, Neuromuscular-Blocking Drugs, Non-Depolarising Blocking Agents, Depolarising Blocking Agents, Cholinesterase Reactivation, Noradrenergic transmission, Adrenoceptor Agonists, α-Adrenoceptor antagonists, 5-Hydroxytryptamine, migraine, Adenosine, purine, Histamine, local hormone, Eicosanoids, Prostanoids, Leukotrienes, Platelet-Activating Factor, Bradykinin, peptide, Neuropeptides, Cytokine, Interferon, Cannabinoids, Endocannabinoids, Nitric oxide, Ischaemic Heart Disease, Antidysrhythmic Drugs, Myocardial Contraction, Anti-Anginal Drugs, Organic Nitrates, Calcium Antagonists, Endothelin, Vasoactive Drugs, Vasodilator Drugs, heart failure, Atherosclerosis, lipoprotein metabolism, Lipoprotein Transport, Lipid-Lowering Drugs, Fibrates, Haemostasis and thrombosis, Blood Coagulation, Warfarin, Platelet Adhesion, Platelet Activation, Antiplatelet Drugs, Adenosine Receptor Antagonists, Fibrinolysis, Thrombolysis, Fibrinolytic Drugs

Topics: Drug – receptor binding, GRADED DOSE RESPONSE CURVE, Agonist, antagonist, COMPETITIVE ANTAGONISM, IRREVERSIBLE ANTAGONISM, QUANTAL DOSE RESPONSE CURVE, Desensibilisation, tachyphylaxis, Tachyphylaxis

Topics: Pharmacokinetics, Pharmacodynamics, Life Cycle of a Drug, Slow Absorption, Faster Absorption, Bioavailability, Depot Binding, Degradation, Excretion, Drug Effectiveness, Dose-response curve, Therapeutic Index, Effective dose, Lethal dose, Effective concentration, Drug Efficacy, Drug potency, Drug-drug Interactions, Cumulative Effects, Additive Effects, Synergistic Effects, Antagonistic Effects, Agonism, Antagonism, drug-receptor interaction

Topics: schizophrenia, dopamine pathways, dopamine, atypical Antipsychotics, typical Antipsychotics, phenothiazines, chloropromazine, haloperidol, haldol, Acute dystonia, akathisia, Tardive dyskinesia, Perioral tremor, Rabbit Syndrome, Alpha-adrenergic receptor blockade, Muscarinic receptor blockade, anticholinergic, antimuscarinic, antihistaminergic, adrenergic antagonism, dopaminergic pathway, Antipsychotic side effects

Topics: Pharmaceutic interaction, Pharmacodynamic interaction, Pharmacokinetic interaction, SYNERGISM, ANTAGONISM, PLASMA PROTEINS, Plasma albumin, DRUG FOOD INTERACTION, DRUG DISEASE INTERACTION